NCT05161195 2026-02-02
Roll-over Study to Allow Continued Access to Ribociclib
Novartis
Phase 4 Active not recruiting
Novartis
Ottawa Hospital Research Institute
Palleos Healthcare GmbH
Fred Hutchinson Cancer Center
Institut Claudius Regaud
Institut Claudius Regaud
Institut Claudius Regaud
AstraZeneca
AstraZeneca
AstraZeneca
AstraZeneca